
Abraham Goorhuis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11668030/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Emergence of <i>Clostridium difficile</i> Infection Due to a New Hypervirulent Strain, Polymerase Chain Reaction Ribotype 078. Clinical Infectious Diseases, 2008, 47, 1162-1170.	2.9	577
2	Import and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae by international travellers (COMBAT study): a prospective, multicentre cohort study. Lancet Infectious Diseases, The, 2017, 17, 78-85.	4.6	340
3	Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. Journal of Antimicrobial Chemotherapy, 2012, 67, 742-748.	1.3	306
4	European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clinical Microbiology and Infection, 2021, 27, S1-S21.	2.8	242
5	Global phylogenetic analysis of Escherichia coli and plasmids carrying the mcr-1 gene indicates bacterial diversity but plasmid restriction. Scientific Reports, 2017, 7, 15364.	1.6	230
6	Travel-associated infection presenting in Europe (2008–12): an analysis of EuroTravNet longitudinal, surveillance data, and evaluation of the effect of the pre-travel consultation. Lancet Infectious Diseases, The, 2015, 15, 55-64.	4.6	206
7	<i>Clostridium difficile</i> PCR ribotype 078 toxinotype V found in diarrhoeal pigs identical to isolates from affected humans. Environmental Microbiology, 2009, 11, 505-511.	1.8	154
8	Serodiagnosis of Zika virus (ZIKV) infections by a novel NS1-based ELISA devoid of cross-reactivity with dengue virus antibodies: a multicohort study of assay performance, 2015 to 2016. Eurosurveillance, 2016, 21, .	3.9	151
9	Long-term sequelae of chikungunya virus disease: A systematic review. Travel Medicine and Infectious Disease, 2017, 15, 8-22.	1.5	136
10	Clostridium difficile PCR Ribotype 078: an Emerging Strain in Humans and in Pigs?. Journal of Clinical Microbiology, 2008, 46, 1157-1158.	1.8	113
11	All-Cause and Disease-Specific Mortality in Hospitalized Patients With Clostridium difficile Infection: A Multicenter Cohort Study. Clinical Infectious Diseases, 2013, 56, 1108-1116.	2.9	113
12	Diagnosis and subtype analysis of Blastocystis sp.in 442 patients in a hospital setting in the Netherlands. BMC Infectious Diseases, 2013, 13, 389.	1.3	86
13	Thrombocytopenia and subcutaneous bleedings in a patient with Zika virus infection. Lancet, The, 2016, 387, 939-940.	6.3	82
14	Incidence of invasive pneumococcal disease in immunocompromised patients: A systematic review and meta-analysis. Travel Medicine and Infectious Disease, 2018, 24, 89-100.	1.5	82
15	A Single 17D Yellow Fever Vaccination Provides Lifelong Immunity; Characterization of Yellow-Fever-Specific Neutralizing Antibody and T-Cell Responses after Vaccination. PLoS ONE, 2016, 11, e0149871.	1.1	80
16	Travel-Associated Zika Virus Disease Acquired in the Americas Through February 2016. Annals of Internal Medicine, 2017, 166, 99.	2.0	67
17	Complications, effectiveness, and long term followâ€up of fecal microbiota transfer by nasoduodenal tube for treatment of recurrent <i>Clostridium difficile</i> infection. United European Gastroenterology Journal, 2017, 5, 868-879.	1.6	64
18	Health Risks of Travelers With Medical Conditions—A Retrospective Analysis. Journal of Travel Medicine, 2012, 19, 104-110.	1.4	58

Abraham Goorhuis

#	Article	IF	CITATIONS
19	The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: A systematic review and meta-analysis. Vaccine, 2018, 36, 5832-5845.	1.7	57
20	Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination - A systematic review and meta-analysis. Travel Medicine and Infectious Disease, 2020, 37, 101868.	1.5	57
21	Higher Prevalence and Faster Progression of Chronic Kidney Disease in Human Immunodeficiency Virus–Infected Middle-Aged Individuals Compared With Human Immunodeficiency Virus–Uninfected Controls. Journal of Infectious Diseases, 2017, 216, 622-631.	1.9	51
22	Prolonged carriage and potential onward transmission of carbapenemase-producing Enterobacteriaceae in Dutch travelers. Future Microbiology, 2016, 11, 857-864.	1.0	50
23	Neuropsychological long-term sequelae of Ebola virus disease survivors – A systematic review. Travel Medicine and Infectious Disease, 2017, 18, 18-23.	1.5	49
24	Response to Hepatitis A Vaccination in Immunocompromised Travelers. Journal of Infectious Diseases, 2015, 212, 378-385.	1.9	46
25	Zika virus and the risk of imported infection in returned travelers: Implications for clinical care. Travel Medicine and Infectious Disease, 2016, 14, 13-15.	1.5	42
26	The Carriage Of Multiresistant Bacteria After Travel (COMBAT) prospective cohort study: methodology and design. BMC Public Health, 2014, 14, 410.	1.2	35
27	Zika virus infection in 18 travellers returning from Surinam and the Dominican Republic, The Netherlands, November 2015–March 2016. Infection, 2016, 44, 797-802.	2.3	35
28	Current challenges in the treatment of severe Clostridium difficile infection: early treatment potential of fecal microbiota transplantation. Therapeutic Advances in Gastroenterology, 2017, 10, 373-381.	1.4	35
29	Faecal microbiota transplantation for <i>Clostridioides difficile</i> infection: Four years' experience of the Netherlands Donor Feces Bank. United European Gastroenterology Journal, 2020, 8, 1236-1247.	1.6	35
30	Incidence and Risk Factors for Invasive Pneumococcal Disease and Community-acquired Pneumonia in Human Immunodeficiency Virus–Infected Individuals in a High-income Setting. Clinical Infectious Diseases, 2020, 71, 41-50.	2.9	28
31	Clostridium difficile infection in returning travellers. Journal of Travel Medicine, 2017, 24, .	1.4	27
32	Travel-related infections presenting in Europe: A 20-year analysis of EuroTravNet surveillance data. Lancet Regional Health - Europe, The, 2021, 1, 100001.	3.0	27
33	Human Transmission of <i>Blastocystis</i> by Fecal Microbiota Transplantation Without Development of Gastrointestinal Symptoms in Recipients. Clinical Infectious Diseases, 2020, 71, 2630-2636.	2.9	25
34	Under-diagnosis of rickettsial disease in clinical practice: A systematic review. Travel Medicine and Infectious Disease, 2018, 26, 7-15.	1.5	23
35	Added value of chest computed tomography in suspected COVID-19: an analysis of 239 patients. European Respiratory Journal, 2020, 56, 2001377.	3.1	22
36	Comparison of the PRNT and an immune fluorescence assay in yellow fever vaccinees receiving immunosuppressive medication. Vaccine, 2016, 34, 1247-1251.	1.7	21

#	Article	IF	CITATIONS
37	Periodic screening of donor faeces with a quarantine period to prevent transmission of multidrug-resistant organisms during faecal microbiota transplantation: a retrospective cohort study. Lancet Infectious Diseases, The, 2021, 21, 711-721.	4.6	21
38	Immunogenicity of the Currently Recommended Pneumococcal Vaccination Schedule in Patients With Inflammatory Bowel Disease. Clinical Infectious Diseases, 2019, 70, 595-604.	2.9	20
39	Destination shapes antibiotic resistance gene acquisitions, abundance increases, and diversity changes in Dutch travelers. Genome Medicine, 2021, 13, 79.	3.6	20
40	Yellow fever vaccination $\hat{a} \in \mathcal{C}$ Once in a lifetime?. Travel Medicine and Infectious Disease, 2017, 15, 1-2.	1.5	19
41	Epidemiology of rabies cases among international travellers, 2013–2019: A retrospective analysis of published reports. Travel Medicine and Infectious Disease, 2020, 36, 101766.	1.5	19
42	Carriage of Blastocystis spp. in travellers - A prospective longitudinal study. Travel Medicine and Infectious Disease, 2019, 27, 87-91.	1.5	18
43	Hepatitis A vaccine immunogenicity in patients using immunosuppressive drugs: A systematic review and meta-analysis. Travel Medicine and Infectious Disease, 2019, 32, 101479.	1.5	18
44	lmmunogenicity of pneumococcal vaccination in HIV infected individuals: A systematic review and meta-analysis. EClinicalMedicine, 2020, 29-30, 100576.	3.2	17
45	Travel-related acquisition of diarrhoeagenic bacteria, enteral viruses and parasites in a prospective cohort of 98 Dutch travellers. Travel Medicine and Infectious Disease, 2017, 19, 33-36.	1.5	16
46	Prevalence and risk factors for carriage of ESBL-producing Enterobacteriaceae in a population of Dutch travellers: A cross-sectional study. Travel Medicine and Infectious Disease, 2020, 33, 101547.	1.5	16
47	Rabies antibody response after two intradermal pre-exposure prophylaxis immunizations: An observational cohort study. Travel Medicine and Infectious Disease, 2018, 22, 36-39.	1.5	15
48	Comparison of equivalent fractional vaccine doses delivered by intradermal and intramuscular or subcutaneous routes: A systematic review. Travel Medicine and Infectious Disease, 2021, 41, 102007.	1.5	13
49	Long-term pneumococcal vaccine immunogenicity following allogeneic hematopoietic stem cell transplantation. Vaccine, 2019, 37, 510-515.	1.7	12
50	Leptospirosis among Returned Travelers: A GeoSentinel Site Survey and Multicenter Analysis—1997–2016. American Journal of Tropical Medicine and Hygiene, 2018, 99, 127-135.	0.6	12
51	Travel-related health problems in the immunocompromised traveller: An exploratory study. Travel Medicine and Infectious Disease, 2018, 25, 50-57.	1.5	10
52	Novel Risk Factors for <i>Clostridium difficile</i> –Associated Disease in a Setting of Endemicity?. Clinical Infectious Diseases, 2008, 47, 429-430.	2.9	9
53	Travel-related leptospirosis in the Netherlands 2009–2016: An epidemiological report and case series. Travel Medicine and Infectious Disease, 2018, 24, 44-50.	1.5	9
54	Risk of acquisition of human diarrhoeagenic Escherichia coli virulence genes in intercontinental travellers: A prospective, multi-centre study. Travel Medicine and Infectious Disease, 2019, 31, 101362.	1.5	9

Abraham Goorhuis

#	Article	IF	CITATIONS
55	COVID-19 treatment in sub-Saharan Africa: If the best is not available, the available becomes the best. Travel Medicine and Infectious Disease, 2020, 37, 101878.	1.5	9
56	Immunogenicity of a 5â€dose pneumococcal vaccination schedule following allogeneic hematopoietic stem cell transplantation. American Journal of Hematology, 2022, 97, 592-602.	2.0	9
57	Pre-travel care for immunocompromised and chronically ill travellers: A retrospective study. Travel Medicine and Infectious Disease, 2017, 19, 37-48.	1.5	8
58	Updated Zika virus recommendations are needed. Lancet, The, 2018, 392, 818-819.	6.3	8
59	Invasive pneumococcal disease among adults with hematological and solid organ malignancies: A population-based cohort study. International Journal of Infectious Diseases, 2021, 106, 237-245.	1.5	8
60	Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers. Clinical Infectious Diseases, 2023, 76, e533-e536.	2.9	7
61	A Modified Case Definition to Facilitate Essential Hospital Care During Ebola Outbreaks. Clinical Infectious Diseases, 2019, 68, 1763-1768.	2.9	6
62	Searching and Finding the Hidden Treasure: A Retrospective Analysis of Rickettsial Disease Among Dutch International Travelers. Clinical Infectious Diseases, 2021, 72, 1171-1178.	2.9	6
63	Long-term Memory Response After a Single Intramuscular Rabies Booster Vaccination 10–24 Years After Primary Immunization. Journal of Infectious Diseases, 2022, 226, 1052-1056.	1.9	6
64	Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy. Vaccines, 2022, 10, 795.	2.1	6
65	Uncommon presentation of Zika fever or co-infection? – Authors' reply. Lancet, The, 2016, 387, 1813-1814.	6.3	4
66	Delayed large local reaction to the adenovirus-vectored (ChAdOx1) vaccine. Travel Medicine and Infectious Disease, 2021, 43, 102093.	1.5	4
67	Incidence and Predictors of Community-Acquired Pneumonia in Patients With Hematological Cancers Between 2016 and 2019. Clinical Infectious Diseases, 2022, 75, 1046-1053.	2.9	4
68	Immunogenicity of the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine in people living with HIV on combination antiretroviral therapy. International Journal of Antimicrobial Agents, 2022, 60, 106629.	1.1	4
69	<i>Editorial Commentary: Clostridium difficile</i> Ribotype 027: An Intrinsically Virulent Strain, but Clinical Virulence Remains to Be Determined at the Bedside. Clinical Infectious Diseases, 2015, 61, 242-243.	2.9	3
70	Zika virus: who's next?. Lancet Infectious Diseases, The, 2016, 16, 1204-1205.	4.6	3
71	Safety and immunogenicity of a recombinant adenovirus vector-based Ebola vaccine. Lancet, The, 2017, 389, 578-580.	6.3	3
72	Ebola 2018 – Implications for travel health advice and relevance for travel medicine. Travel Medicine and Infectious Disease, 2018, 24, 1-3.	1.5	3

#	Article	IF	CITATIONS
73	No detection of Zika virus infection in asymptomatic Dutch military personnel after deployment in high endemic areas (Belize, Curacao, Saint Martin) from December 2016 to December 2017. Travel Medicine and Infectious Disease, 2019, 27, 119-120.	1.5	2
74	A review of severe thrombocytopenia in Zika patients – Pathophysiology, treatment and outcome. Travel Medicine and Infectious Disease, 2022, 45, 102231.	1.5	2
75	Reply to Zhao and Miao and to Chen et al." Is the rabies virus neutralizing antibody titerstable during long-term storage?. Travel Medicine and Infectious Disease, 2019, 32, 101502.	1.5	1
76	Antibody response in Dutch marines to a single intramuscular rabies booster immunization 1–2.5 years after an intradermal pre-exposure schedule: An observational study. Travel Medicine and Infectious Disease, 2020, 38, 101907.	1.5	1
77	Can dengue virus be sexually transmitted?. Travel Medicine and Infectious Disease, 2020, 38, 101753.	1.5	1
78	SARS-CoV-2 vaccination for patients with inflammatory bowel disease. The Lancet Gastroenterology and Hepatology, 2021, 6, 523.	3.7	1